Safety study of oral azacitidine for AML in Korea
Part of Blood & lymphatic, Cancer clinical trials.
This study is monitoring the safety of the drug oral azacitidine (also called Onureg) when given as maintenance therapy to adults with acute myeloid leukemia (AML). It is designed to track how well patients tolerate the medicine in real-world use in Korea.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older
- You have been prescribed oral azacitidine exactly as approved for use in Korea
- You have signed a consent form agreeing to join this safety study
- You are not taking oral azacitidine for any condition not officially approved in Korea
- You do not have any medical reason that would make oral azacitidine unsafe for you, as listed in the official prescribing information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication (azacitidine) for people with AML who are in remission and planning a stem cell transplant. It focuses on patients who face health disparities, such as financial or access barriers, to help make transplant more successful for everyone.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This trial tests whether a maintenance treatment with a hypomethylating agent can help keep favorable-risk acute myeloid leukemia (AML) patients in remission after they have completed initial therapy. It is designed for patients who have achieved negative minimal residual disease (MRD) and have not received a stem cell transplant.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This study looks at how leukemia cells become resistant to two common drug combinations: azacitidine plus venetoclax or azacitidine plus ivosidenib. It is for people with newly diagnosed AML who are about to start one of these treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.